These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22185350)

  • 1. Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.
    Hassan MK; Watari H; Han Y; Mitamura T; Hosaka M; Wang L; Tanaka S; Sakuragi N
    J Exp Clin Cancer Res; 2011 Dec; 30(1):113. PubMed ID: 22185350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel.
    Hassan MK; Watari H; Christenson L; Bettuzzi S; Sakuragi N
    Tumour Biol; 2011 Oct; 32(5):1031-47. PubMed ID: 21761117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.
    So A; Sinnemann S; Huntsman D; Fazli L; Gleave M
    Mol Cancer Ther; 2005 Dec; 4(12):1837-49. PubMed ID: 16373699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer.
    Park DC; Yeo SG; Wilson MR; Yerbury JJ; Kwong J; Welch WR; Choi YK; Birrer MJ; Mok SC; Wong KK
    Neoplasia; 2008 Sep; 10(9):964-72. PubMed ID: 18714397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer.
    Wei L; Xue T; Wang J; Chen B; Lei Y; Huang Y; Wang H; Xin X
    Int J Cancer; 2009 Aug; 125(4):791-806. PubMed ID: 19391138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J.
    Lourda M; Trougakos IP; Gonos ES
    Int J Cancer; 2007 Feb; 120(3):611-22. PubMed ID: 17096323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
    Lamoureux F; Baud'huin M; Ory B; Guiho R; Zoubeidi A; Gleave M; Heymann D; Rédini F
    Oncotarget; 2014 Sep; 5(17):7805-19. PubMed ID: 25138053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
    Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
    PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of clusterin expression in advanced-stage cervical cancer treated with curative intended radiotherapy.
    Watari H; Kinoshita R; Han Y; Wang L; Hosaka M; Taguchi H; Tsuchiya K; Tanaka S; Shirato H; Sakuragi N
    Int J Gynecol Cancer; 2012 Mar; 22(3):465-70. PubMed ID: 21633299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer.
    Fu Y; Lai Y; Wang Q; Liu X; He W; Zhang H; Fan C; Yang G
    Mol Med Rep; 2013 Jun; 7(6):1726-32. PubMed ID: 23616046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
    Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
    Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
    Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clusterin (CLU) and lung cancer.
    Panico F; Rizzi F; Fabbri LM; Bettuzzi S; Luppi F
    Adv Cancer Res; 2009; 105():63-76. PubMed ID: 19879423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clusterin confers paclitaxel resistance in cervical cancer.
    Park DC; Yeo SG; Shin EY; Mok SC; Kim DH
    Gynecol Oncol; 2006 Dec; 103(3):996-1000. PubMed ID: 16890274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
    Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
    Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
    Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC
    Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832
    [No Abstract]   [Full Text] [Related]  

  • 19. Knockdown of clusterin expression increases the in vitro sensitivity of human prostate cancer cells to paclitaxel.
    Chun YJ
    J Toxicol Environ Health A; 2014; 77(22-24):1443-50. PubMed ID: 25343293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
    Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.